B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure
暂无分享,去创建一个
[1] D. Webb,et al. Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[2] D. Vaughan,et al. Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin , 2003, Circulation.
[3] D. Vaughan,et al. ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time , 2002, Hypertension.
[4] D. Newby,et al. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. , 2002, Journal of the American College of Cardiology.
[5] R. Ye,et al. Up-Regulation of Functional Kinin B1 Receptors in Allergic Airway Inflammation1 , 2002, The Journal of Immunology.
[6] J. Schanstra,et al. Induction of Functional Bradykinin B1-Receptors in Normotensive Rats and Mice Under Chronic Angiotensin-Converting Enzyme Inhibitor Treatment , 2002, Circulation.
[7] J. Isner,et al. Targeting Kinin B1 Receptor for Therapeutic Neovascularization , 2002, Circulation.
[8] D. Webb,et al. Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure , 2001, Circulation.
[9] IrenaDuka,et al. Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension , 2001 .
[10] H. Gavras,et al. Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension , 2001, Circulation research.
[11] D. Deblois,et al. Endotoxin sensitization to kinin B1 receptor agonist in a non‐human primate model: haemodynamic and pro‐inflammatory effects , 2001, British journal of pharmacology.
[12] A. Ahluwalia,et al. Kinin B1 receptors and the cardiovascular system: regulation of expression and function , 2000 .
[13] D. Vaughan,et al. Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway , 2000, Circulation.
[14] A. Ahluwalia,et al. Association between Kinin B1 Receptor Expression and Leukocyte Trafficking across Mouse Mesenteric Postcapillary Venules , 2000, The Journal of experimental medicine.
[15] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[16] F. Barbe,et al. Stimulation of Bradykinin B1 Receptors Induces Vasodilation in Conductance and Resistance Coronary Vessels in Conscious Dogs Comparison With B2 Receptor Stimulation , 2000 .
[17] T. Walther,et al. Upregulation of bradykinin B1‐receptor expression after myocardial infarction , 2000, British journal of pharmacology.
[18] A. Ahluwalia,et al. Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. , 2000, Cardiovascular research.
[19] F. Barbe,et al. Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. , 2000, Circulation.
[20] J. Morrow,et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. , 1998, The New England journal of medicine.
[21] S. Sardi,et al. Bradykinin B1 receptors in human umbilical vein: pharmacological evidence of up-regulation, and induction by interleukin-1 beta. , 1998, European journal of pharmacology.
[22] D. Bachvarov,et al. The B1 receptors for kinins. , 1998, Pharmacological reviews.
[23] B. Stein. ACE inhibition and heart failure. , 1998, Circulation.
[24] D. Webb,et al. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. , 1997, Cardiovascular research.
[25] D. Webb,et al. An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium , 1997, Thrombosis and Haemostasis.
[26] W. Chandler,et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. , 1997, Circulation.
[27] K. Bhoola,et al. Kinin receptors in human vascular tissue: their role in atheromatous disease. , 1997, Immunopharmacology.
[28] A. Pizard,et al. Receptors for kinins in the human isolated umbilical vein , 1996, British journal of pharmacology.
[29] T. Cocks,et al. SPECIAL REPORT Endothelium‐dependent relaxation to the B1 kinin receptor agonist des‐Arg ‐bradykinin in human coronary arteries , 1995 .
[30] T. Cocks,et al. Endothelium-dependent relaxation to the B1 kinin receptor agonist des-Arg9-bradykinin in human coronary arteries. , 1995, British journal of pharmacology.
[31] R. Nadeau,et al. Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs , 1993, British journal of pharmacology.
[32] F. Marceau,et al. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. , 1991, The Journal of pharmacology and experimental therapeutics.
[33] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[34] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.